Skip to main content

BBC

ETF
—
—

Performance overview

BBC Price
Price Chart

Forward-looking statistics

Beta
1.33
Risk
35.31%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Fund info

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Investing methodPassively Managed
DiversifiedNo
Expense ratio0.75%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$851K
Avg trading volume (10 day)$791K
Put-call ratioN/A

Macro factor sensitivity

Growth+1.3
Credit+5.3
Liquidity+0.2
Inflation-1.9
Commodities-0.5
Interest Rates-1.9

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayDecember 20, 2024

News

6 Best-Performing ETFs of Last Week

Wall Street delivered mixed-to-downbeat performance last week thanks to Powell's warning of stagflation, rise of auto stocks on policy hopes, NVIDIA's $5.5B hit on export curb and upbeat retail sales.

Zacks Investment Research (April 21, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free